Showing results (2371-2380 of 2,942) with videos related to

Sort By:
Pageof 295
JAMA Health Forum|May 26, 2023
Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of TreatmentBradley D Stein, Brendan K Saloner, Olivia K Golan, et al.
Ciba Foundation Symposium|January 1, 1992
Inositol lipids and phosphates in the proliferation and differentiation of lymphocytes and myeloid cellsR H Michell, L A Conroy, M Finney, et al.
The Journal of Clinical Investigation|December 13, 2006
The type III TGF-beta receptor suppresses breast cancer progressionMei Dong, Tam How, Kellye C Kirkbride, et al.
Sleep Medicine Reviews|August 3, 2020
Economic evaluation of cognitive behavioural therapy for insomnia (CBT-I) for improving health outcomes in adult populations: A systematic reviewAndrea N Natsky, Andrew Vakulin, Ching L Chai-Coetzer, et al.
Acta Crystallographica. Section D, Biological Crystallography|May 1, 1997
Partial improvement of crystal quality for microgravity-grown apocrustacyanin C1E H Snell, A Cassetta, J R Helliwell, et al.
BMJ (Clinical Research Ed.)|March 6, 2020
Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluationElizabeth M Oliva, Thomas Bowe, Ajay Manhapra, et al.
The British Journal of Ophthalmology|May 1, 1997
Influence of topical human epidermal growth factor on postkeratoplasty re-epithelialisationM M Dellaert, T A Casey, S Wiffen, et al.
European Journal of Immunology|September 1, 1993
Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 inductionM J Holder, H Wang, A E Milner, et al.
Circulation|January 1, 1989
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesD J Gordon, J L Probstfield, R J Garrison, et al.
Clinical and Experimental Rheumatology|August 26, 2014
Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trialJ Gordon, U Udeh, K Doobay, et al.
Pageof 295